Menu
/REGISTER
Montecito
Nixon Peabody
Pac Premier
Loading...
You are here:  Home  >  'Parsabiv'
Latest

New drugs boost profits at Amgen as two executives leave company

By   /  Friday, August 3rd, 2018  /  Central Coast Health Watch, Earnings, East Ventura County, left, Tri-County Public Companies  /  Comments Off on New drugs boost profits at Amgen as two executives leave company

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Drug sales for biotech giant Amgen boost bottom line

By   /  Friday, February 10th, 2017  /  Central Coast Health Watch, Earnings, left, Technology, Tri-County Public Companies  /  Comments Off on Drug sales for biotech giant Amgen boost bottom line

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

FDA approves Amgen’s Parsabiv drug to treat chronic kidney disease

By   /  Tuesday, February 7th, 2017  /  Central Coast Health Watch, Latest news  /  Comments Off on FDA approves Amgen’s Parsabiv drug to treat chronic kidney disease

The U.S. Food and Drug Administration approved Amgen’s Parsabiv drug to treat patients with chronic kidney disease, the company announced on Feb. 7. The Thousand Oaks-based biotech company’s Parsabiv is the first therapy approved for the treatment of secondary hyperparathyroidism for patients on hemodialysis in 12 years, Amgen said. “We are excited about today’s approval Read More →

Read More →